论文部分内容阅读
目的探讨依达拉奉联合血塞通对急性脑梗死患者凝血纤溶系统的影响。方法将79例急性脑梗死患者随机分为治疗组和对照组,对照组39例,给予注射用血塞通每日0.4 g静脉滴注,治疗组40例,在对照组用药基础上加用依达拉奉注射液每日30 mg静脉滴注,疗程14 d。治疗前及治疗后第14天分别测定患者的凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、凝血酶时间(TT)和纤维蛋白原(Fg),并进行美国国立卫生研究院卒中量表(NIHSS)评分。结果治疗第14天,治疗组血Fg浓度及NIHSS评分较对照组明显降低(P<0.05),血浆PT、APTT和TT值两组差异无统计学意义(P>0.05)。结论依达拉奉对血塞通治疗急性脑梗死患者血浆PT、APTT和TT值无明显影响,但能够降低患者血浆Fg的浓度,进一步改善神经功能缺损症状。
Objective To investigate the effect of Edaravone and Xuesaitong on coagulation and fibrinolytic system in patients with acute cerebral infarction. Methods A total of 79 patients with acute cerebral infarction were randomly divided into treatment group and control group. 39 patients in the control group were given 0.4g intravenous injection of Xuesaitong injection daily, and 40 patients in the treatment group were treated with the control group Da Vaton injection 30 mg daily intravenous infusion, treatment 14 d. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and fibrinogen (Fg) were measured before treatment and on the 14th day after treatment, and the American National Institutes of Health Hospital Stroke Scale (NIHSS) score. Results On the 14th day of treatment, the Fg concentration and NIHSS score in the treatment group were significantly lower than those in the control group (P <0.05). There were no significant differences in the plasma PT, APTT and TT values between the two groups (P> 0.05). Conclusion Edaravone has no significant effect on plasma PT, APTT and TT in patients with acute cerebral infarction treated with Xuesaitong, but can reduce the concentration of plasma Fg in patients and further improve the symptoms of neurological deficits.